Beranda › Obesitas › Connecticut
Uji klinis Obesitas di Connecticut
22 studi untuk Obesitas mencari peserta di lokasi di Connecticut.
Kota di Connecticut
Teks studi resmi (Bahasa Inggris)
Investigation of Egg Intake and the Relationship Between Gut Microbiome, Metabolic, and Immune Profiles
- University of Connecticut, Storrs
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 50 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07844616A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Yale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven
- Stamford Therapeutics Consortium, Stamford
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- New England Research Associates, LLC, Bridgeport
- CMR of Greater New Haven, LLC, Hamden
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- New England Research Associates, LLC, Bridgeport
- Yale University School of Medicine, New Haven
- Chase Medical Research, LLC, Waterbury
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Chase Medical Research, LLC, Waterbury
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Stamford Therapeutics Consortium, Stamford
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07589608Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Cardiology Associates of Fairfield County PC, Stamford
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Yale University, New Haven
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Waterbury
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Stamford Therapeutics Consortium, Stamford
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06143956Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Stamford
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Chase Medical Research LLC, Waterbury
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Bridgeport
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07284875Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Hamden
- Kailera Clinical Site, Stamford
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07284979AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Chase Medical Research LLC, Waterbury
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07509307A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
- UConn Health, Farmington
- Hartford HealthCare, Hartford
- University of Connecticut, Storrs
Menerima peserta
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07238556Motivating Increases in Physical Activity for Prevention of Weight Regain After Metabolic Bariatric Surgery
- Hartford HealthCare, Hartford
Menerima peserta
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06484621Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
- Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven
Menerima pesertaFase 2
Usia 18 hingga 30 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT06411210A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Chase Medical Research LLC, Hamden
- Chase Medical Research LLC, Waterbury
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07481630Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life
- Yale University, New Haven
Menerima pesertaSukarelawan sehat diterima
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT07376655New Mechanisms of Obesity
- Yale University, New Haven
Menerima peserta
Usia 15 hingga 22 · Semua jenis kelamin · Diperbarui 28 Jan 2026 · NCT06768827Craving Network Neurofeedback
- Yale MRRC Anlyan Center, New Haven
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 3 Des 2025 · NCT06426693Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.